Development and Evaluation of Patient Education and Counselling Intervention for Cardiovascular Patients recovered from COVID-19
Phase 3
- Conditions
- Health Condition 1: I00-I99- Diseases of the circulatory system
- Registration Number
- CTRI/2023/05/053042
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with cardiovascular disease after recovered from COVID-19
Exclusion Criteria
1. Patients having cardiovascular disease before COVID-19 exposure
2. Pregnant women and immunocompromised patients
3. Patients who are not willing to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the impact of pharmaceutical care on humanistic and clinical outcomes in patients recovered from COVID-19Timepoint: At the completion of study
- Secondary Outcome Measures
Name Time Method 1. To analyze the risk factors associated with cardiovascular problems in patients recovered from COVID-19 <br/ ><br>2. To identify and resolve drug-related problems in patients recovered from COVID-19 <br/ ><br>Timepoint: At the completion of study